Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis
Coronavirus disease 2019 (COVID-19) has caused an enormous loss of life worldwide. The spike protein of the severe acute respiratory syndrome coronavirus 2 is the cause of its virulence. Bamlanivimab, a recombinant monoclonal antibody, has been used alone or in combination with etesevimab to provide...
Saved in:
| Published in | PeerJ (San Francisco, CA) Vol. 11; p. e15344 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
PeerJ. Ltd
08.05.2023
PeerJ Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2167-8359 2167-8359 |
| DOI | 10.7717/peerj.15344 |
Cover
| Abstract | Coronavirus disease 2019 (COVID-19) has caused an enormous loss of life worldwide. The spike protein of the severe acute respiratory syndrome coronavirus 2 is the cause of its virulence. Bamlanivimab, a recombinant monoclonal antibody, has been used alone or in combination with etesevimab to provide passive immunity and improve clinical outcomes. A systematic review and meta-analysis was conducted to investigate the therapeutic effects of bamlanivimab with or without etesevimab (BAM/ETE) treatment.
Our study was registered in PROSPERO (registry number CRD42021270206). We searched the following electronic databases, without language restrictions, until January 2023: PubMed, Embase, medRxiv, and the Cochrane database. A systematic review and meta-analysis was conducted based on the search results.
Eighteen publications with a total of 28,577 patients were identified. Non-hospitalized patients given bamlanivimab with or without etesevimab had a significantly lower risk of subsequent hospitalization (18 trials, odds ratio (OR): 0.37, 95% confidence interval (CI): [0.29-0.49],
: 69%;
< 0.01) and mortality (15 trials, OR: 0.27, 95% CI [0.17-0.43],
: 0%;
= 0.85). Bamlanivimab monotherapy also reduced the subsequent risk of hospitalization (16 trials, OR: 0.43, 95% CI [0.34-0.54],
: 57%;
= 0.01) and mortality (14 trials, OR: 0.28, 95% CI [0.17-0.46],
: 0%;
= 0.9). Adverse events from these medications were uncommon and tolerable.
In this meta-analysis, we found the use of bamlanivimab with or without etesevimab contributed to a significantly-reduced risk of subsequent hospitalization and mortality in non-hospitalized COVID-19 patients. However, resistance to monoclonal antibodies was observed in COVID-19 variants, resulting in the halting of the clinical use of BAM/ETE. Clinicians' experiences with BAM/ETE indicate the importance of genomic surveillance. BAM/ETE may be repurposed as a potential component of a cocktail regimen in treating future COVID variants. |
|---|---|
| AbstractList | Coronavirus disease 2019 (COVID-19) has caused an enormous loss of life worldwide. The spike protein of the severe acute respiratory syndrome coronavirus 2 is the cause of its virulence. Bamlanivimab, a recombinant monoclonal antibody, has been used alone or in combination with etesevimab to provide passive immunity and improve clinical outcomes. A systematic review and meta-analysis was conducted to investigate the therapeutic effects of bamlanivimab with or without etesevimab (BAM/ETE) treatment.
Our study was registered in PROSPERO (registry number CRD42021270206). We searched the following electronic databases, without language restrictions, until January 2023: PubMed, Embase, medRxiv, and the Cochrane database. A systematic review and meta-analysis was conducted based on the search results.
Eighteen publications with a total of 28,577 patients were identified. Non-hospitalized patients given bamlanivimab with or without etesevimab had a significantly lower risk of subsequent hospitalization (18 trials, odds ratio (OR): 0.37, 95% confidence interval (CI): [0.29-0.49],
: 69%;
< 0.01) and mortality (15 trials, OR: 0.27, 95% CI [0.17-0.43],
: 0%;
= 0.85). Bamlanivimab monotherapy also reduced the subsequent risk of hospitalization (16 trials, OR: 0.43, 95% CI [0.34-0.54],
: 57%;
= 0.01) and mortality (14 trials, OR: 0.28, 95% CI [0.17-0.46],
: 0%;
= 0.9). Adverse events from these medications were uncommon and tolerable.
In this meta-analysis, we found the use of bamlanivimab with or without etesevimab contributed to a significantly-reduced risk of subsequent hospitalization and mortality in non-hospitalized COVID-19 patients. However, resistance to monoclonal antibodies was observed in COVID-19 variants, resulting in the halting of the clinical use of BAM/ETE. Clinicians' experiences with BAM/ETE indicate the importance of genomic surveillance. BAM/ETE may be repurposed as a potential component of a cocktail regimen in treating future COVID variants. Background Coronavirus disease 2019 (COVID-19) has caused an enormous loss of life worldwide. The spike protein of the severe acute respiratory syndrome coronavirus 2 is the cause of its virulence. Bamlanivimab, a recombinant monoclonal antibody, has been used alone or in combination with etesevimab to provide passive immunity and improve clinical outcomes. A systematic review and meta-analysis was conducted to investigate the therapeutic effects of bamlanivimab with or without etesevimab (BAM/ETE) treatment. Methods Our study was registered in PROSPERO (registry number CRD42021270206). We searched the following electronic databases, without language restrictions, until January 2023: PubMed, Embase, medRxiv, and the Cochrane database. A systematic review and meta-analysis was conducted based on the search results. Results Eighteen publications with a total of 28,577 patients were identified. Non-hospitalized patients given bamlanivimab with or without etesevimab had a significantly lower risk of subsequent hospitalization (18 trials, odds ratio (OR): 0.37, 95% confidence interval (CI): [0.29-0.49], I.sup.2 : 69%; p < 0.01) and mortality (15 trials, OR: 0.27, 95% CI [0.17-0.43], I.sup.2 : 0%; p = 0.85). Bamlanivimab monotherapy also reduced the subsequent risk of hospitalization (16 trials, OR: 0.43, 95% CI [0.34-0.54], I.sup.2 : 57%; p = 0.01) and mortality (14 trials, OR: 0.28, 95% CI [0.17-0.46], I.sup.2 : 0%; p = 0.9). Adverse events from these medications were uncommon and tolerable. Conclusions In this meta-analysis, we found the use of bamlanivimab with or without etesevimab contributed to a significantly-reduced risk of subsequent hospitalization and mortality in non-hospitalized COVID-19 patients. However, resistance to monoclonal antibodies was observed in COVID-19 variants, resulting in the halting of the clinical use of BAM/ETE. Clinicians' experiences with BAM/ETE indicate the importance of genomic surveillance. BAM/ETE may be repurposed as a potential component of a cocktail regimen in treating future COVID variants. Background Coronavirus disease 2019 (COVID-19) has caused an enormous loss of life worldwide. The spike protein of the severe acute respiratory syndrome coronavirus 2 is the cause of its virulence. Bamlanivimab, a recombinant monoclonal antibody, has been used alone or in combination with etesevimab to provide passive immunity and improve clinical outcomes. A systematic review and meta-analysis was conducted to investigate the therapeutic effects of bamlanivimab with or without etesevimab (BAM/ETE) treatment. Methods Our study was registered in PROSPERO (registry number CRD42021270206). We searched the following electronic databases, without language restrictions, until January 2023: PubMed, Embase, medRxiv, and the Cochrane database. A systematic review and meta-analysis was conducted based on the search results. Results Eighteen publications with a total of 28,577 patients were identified. Non-hospitalized patients given bamlanivimab with or without etesevimab had a significantly lower risk of subsequent hospitalization (18 trials, odds ratio (OR): 0.37, 95% confidence interval (CI): [0.29–0.49], I2: 69%; p < 0.01) and mortality (15 trials, OR: 0.27, 95% CI [0.17–0.43], I2: 0%; p = 0.85). Bamlanivimab monotherapy also reduced the subsequent risk of hospitalization (16 trials, OR: 0.43, 95% CI [0.34–0.54], I2: 57%; p = 0.01) and mortality (14 trials, OR: 0.28, 95% CI [0.17–0.46], I2: 0%; p = 0.9). Adverse events from these medications were uncommon and tolerable. Conclusions In this meta-analysis, we found the use of bamlanivimab with or without etesevimab contributed to a significantly-reduced risk of subsequent hospitalization and mortality in non-hospitalized COVID-19 patients. However, resistance to monoclonal antibodies was observed in COVID-19 variants, resulting in the halting of the clinical use of BAM/ETE. Clinicians’ experiences with BAM/ETE indicate the importance of genomic surveillance. BAM/ETE may be repurposed as a potential component of a cocktail regimen in treating future COVID variants. Coronavirus disease 2019 (COVID-19) has caused an enormous loss of life worldwide. The spike protein of the severe acute respiratory syndrome coronavirus 2 is the cause of its virulence. Bamlanivimab, a recombinant monoclonal antibody, has been used alone or in combination with etesevimab to provide passive immunity and improve clinical outcomes. A systematic review and meta-analysis was conducted to investigate the therapeutic effects of bamlanivimab with or without etesevimab (BAM/ETE) treatment. Our study was registered in PROSPERO (registry number CRD42021270206). We searched the following electronic databases, without language restrictions, until January 2023: PubMed, Embase, medRxiv, and the Cochrane database. A systematic review and meta-analysis was conducted based on the search results. Eighteen publications with a total of 28,577 patients were identified. Non-hospitalized patients given bamlanivimab with or without etesevimab had a significantly lower risk of subsequent hospitalization (18 trials, odds ratio (OR): 0.37, 95% confidence interval (CI): [0.29-0.49], I.sup.2 : 69%; p < 0.01) and mortality (15 trials, OR: 0.27, 95% CI [0.17-0.43], I.sup.2 : 0%; p = 0.85). Bamlanivimab monotherapy also reduced the subsequent risk of hospitalization (16 trials, OR: 0.43, 95% CI [0.34-0.54], I.sup.2 : 57%; p = 0.01) and mortality (14 trials, OR: 0.28, 95% CI [0.17-0.46], I.sup.2 : 0%; p = 0.9). Adverse events from these medications were uncommon and tolerable. In this meta-analysis, we found the use of bamlanivimab with or without etesevimab contributed to a significantly-reduced risk of subsequent hospitalization and mortality in non-hospitalized COVID-19 patients. However, resistance to monoclonal antibodies was observed in COVID-19 variants, resulting in the halting of the clinical use of BAM/ETE. Clinicians' experiences with BAM/ETE indicate the importance of genomic surveillance. BAM/ETE may be repurposed as a potential component of a cocktail regimen in treating future COVID variants. Coronavirus disease 2019 (COVID-19) has caused an enormous loss of life worldwide. The spike protein of the severe acute respiratory syndrome coronavirus 2 is the cause of its virulence. Bamlanivimab, a recombinant monoclonal antibody, has been used alone or in combination with etesevimab to provide passive immunity and improve clinical outcomes. A systematic review and meta-analysis was conducted to investigate the therapeutic effects of bamlanivimab with or without etesevimab (BAM/ETE) treatment.BackgroundCoronavirus disease 2019 (COVID-19) has caused an enormous loss of life worldwide. The spike protein of the severe acute respiratory syndrome coronavirus 2 is the cause of its virulence. Bamlanivimab, a recombinant monoclonal antibody, has been used alone or in combination with etesevimab to provide passive immunity and improve clinical outcomes. A systematic review and meta-analysis was conducted to investigate the therapeutic effects of bamlanivimab with or without etesevimab (BAM/ETE) treatment.Our study was registered in PROSPERO (registry number CRD42021270206). We searched the following electronic databases, without language restrictions, until January 2023: PubMed, Embase, medRxiv, and the Cochrane database. A systematic review and meta-analysis was conducted based on the search results.MethodsOur study was registered in PROSPERO (registry number CRD42021270206). We searched the following electronic databases, without language restrictions, until January 2023: PubMed, Embase, medRxiv, and the Cochrane database. A systematic review and meta-analysis was conducted based on the search results.Eighteen publications with a total of 28,577 patients were identified. Non-hospitalized patients given bamlanivimab with or without etesevimab had a significantly lower risk of subsequent hospitalization (18 trials, odds ratio (OR): 0.37, 95% confidence interval (CI): [0.29-0.49], I2: 69%; p < 0.01) and mortality (15 trials, OR: 0.27, 95% CI [0.17-0.43], I2: 0%; p = 0.85). Bamlanivimab monotherapy also reduced the subsequent risk of hospitalization (16 trials, OR: 0.43, 95% CI [0.34-0.54], I2: 57%; p = 0.01) and mortality (14 trials, OR: 0.28, 95% CI [0.17-0.46], I2: 0%; p = 0.9). Adverse events from these medications were uncommon and tolerable.ResultsEighteen publications with a total of 28,577 patients were identified. Non-hospitalized patients given bamlanivimab with or without etesevimab had a significantly lower risk of subsequent hospitalization (18 trials, odds ratio (OR): 0.37, 95% confidence interval (CI): [0.29-0.49], I2: 69%; p < 0.01) and mortality (15 trials, OR: 0.27, 95% CI [0.17-0.43], I2: 0%; p = 0.85). Bamlanivimab monotherapy also reduced the subsequent risk of hospitalization (16 trials, OR: 0.43, 95% CI [0.34-0.54], I2: 57%; p = 0.01) and mortality (14 trials, OR: 0.28, 95% CI [0.17-0.46], I2: 0%; p = 0.9). Adverse events from these medications were uncommon and tolerable.In this meta-analysis, we found the use of bamlanivimab with or without etesevimab contributed to a significantly-reduced risk of subsequent hospitalization and mortality in non-hospitalized COVID-19 patients. However, resistance to monoclonal antibodies was observed in COVID-19 variants, resulting in the halting of the clinical use of BAM/ETE. Clinicians' experiences with BAM/ETE indicate the importance of genomic surveillance. BAM/ETE may be repurposed as a potential component of a cocktail regimen in treating future COVID variants.ConclusionsIn this meta-analysis, we found the use of bamlanivimab with or without etesevimab contributed to a significantly-reduced risk of subsequent hospitalization and mortality in non-hospitalized COVID-19 patients. However, resistance to monoclonal antibodies was observed in COVID-19 variants, resulting in the halting of the clinical use of BAM/ETE. Clinicians' experiences with BAM/ETE indicate the importance of genomic surveillance. BAM/ETE may be repurposed as a potential component of a cocktail regimen in treating future COVID variants. |
| ArticleNumber | e15344 |
| Audience | Academic |
| Author | Tai, Yu-Lin Chi, Hsin Huang, Ya-Ning Huang, Shih-Yu Liu, Lawrence Yu-Min Chen, Chung-Chu Lei, Wei-Te Chiu, Nan-Chang Weng, Shun-Long Lin, Chien-Yu Lee, Ming-Dar |
| Author_xml | – sequence: 1 givenname: Yu-Lin surname: Tai fullname: Tai, Yu-Lin organization: Pediatrics, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan, Pediatrics, Hsinchu Municipal MacKay Children’s Hospital, Hsinchu, Taiwan – sequence: 2 givenname: Ming-Dar surname: Lee fullname: Lee, Ming-Dar organization: Pediatrics, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan, Pediatrics, Hsinchu Municipal MacKay Children’s Hospital, Hsinchu, Taiwan – sequence: 3 givenname: Hsin surname: Chi fullname: Chi, Hsin organization: Medicine, MacKay Medical College, New Taipei, Taiwan, Pediatrics, MacKay Children’s Hospital, Taipei, Taiwan – sequence: 4 givenname: Nan-Chang surname: Chiu fullname: Chiu, Nan-Chang organization: Medicine, MacKay Medical College, New Taipei, Taiwan, Pediatrics, MacKay Children’s Hospital, Taipei, Taiwan – sequence: 5 givenname: Wei-Te orcidid: 0000-0003-1677-8901 surname: Lei fullname: Lei, Wei-Te organization: Pediatrics, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan, Pediatrics, Hsinchu Municipal MacKay Children’s Hospital, Hsinchu, Taiwan, Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan – sequence: 6 givenname: Shun-Long surname: Weng fullname: Weng, Shun-Long organization: Medicine, MacKay Medical College, New Taipei, Taiwan, Department of Obstetrics and Gynecology, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan – sequence: 7 givenname: Lawrence Yu-Min surname: Liu fullname: Liu, Lawrence Yu-Min organization: Medicine, MacKay Medical College, New Taipei, Taiwan, Department of Internal Medicine, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan – sequence: 8 givenname: Chung-Chu orcidid: 0000-0003-4415-7811 surname: Chen fullname: Chen, Chung-Chu organization: Department of Internal Medicine, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan, Teaching Center of Natural Science, Minghsin University of Science and Technology, Hsinchu, Taiwan – sequence: 9 givenname: Shih-Yu surname: Huang fullname: Huang, Shih-Yu organization: Department of Internal Medicine, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan – sequence: 10 givenname: Ya-Ning surname: Huang fullname: Huang, Ya-Ning organization: Pediatrics, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan, Pediatrics, Hsinchu Municipal MacKay Children’s Hospital, Hsinchu, Taiwan – sequence: 11 givenname: Chien-Yu orcidid: 0000-0003-4630-8724 surname: Lin fullname: Lin, Chien-Yu organization: Pediatrics, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan, Pediatrics, Hsinchu Municipal MacKay Children’s Hospital, Hsinchu, Taiwan, Medicine, MacKay Medical College, New Taipei, Taiwan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37180576$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkk1v1DAQQCNUREvpiTuyhISQ0C527Hz1gqqlQKVKvQBXa-xMuq6SeImdVsuf4i8y2bSoi5ocEs28eZmJ52Vy0Psek-S14MuiEMXHDeJwsxSZVOpZcpSKvFiUMqsOHr0fJich3HC6yjTnpXyRHMpClDwr8qPkz3nToI2B-YYZ6Fro3a3rwDBo6UPMD8z1zPrOuB6i8z27c3HNMGLAmaNQGE3AXyP2ka192LgIrfs909DXrPPDFInbSeXHuKEUsWFWra5-XnxeiOqUAQvbELGjtGUD6fFurscIC-ih3QYXXiXPG2gDntw_j5MfX86_r74tLq--XqzOLhc2U3lcNHUDspKG5s1lI3KTgwFrcoNKmbJUeYZooZGYoirRAOeqqgW3eZVWyDnK4-Ri9tYebvRmoFmHrfbg9C7gh2sNAzXaopZKQNYIkfK0VlxmwI2qgOcgskIVanJ9ml2b0XRYWxp-gHZPup_p3Vpf-1stuCgUzyUZ3t8bBk8_OkTduWCxpeNCPwadlkKWZcF5RujbGb0G6s31jSelnXB9VqhSKZFlE7V8gqK7xs5ZOvnGUXyv4N2jgjVCG9fBt-N0ymEffPN42H9TPqwcAWIG7OBDGLDRljZm8lALrqWh9bTZerfZerfZVPPhv5oH7VP0X40Z_M4 |
| CitedBy_id | crossref_primary_10_2174_0113816128334441241108050528 crossref_primary_10_61186_umj_34_11_8 crossref_primary_10_33084_bjop_v7i4_6365 crossref_primary_10_61186_umj_35_4_250 |
| Cites_doi | 10.7759/cureus.14933 10.1080/17460441.2021.1960819 10.1056/NEJMe2034495 10.1101/2021.05.23.21257670 10.1172/jci.insight.97844 10.3390/ijms23010029 10.1016/j.ijantimicag.2020.106103 10.14336/AD.2022.0205 10.1016/j.ijantimicag.2020.105924 10.1136/bmj.n71 10.1093/ofid/ofab512 10.1101/2022.03.10.22272100 10.1056/NEJMoa2033130 10.1136/bmj.m2980 10.1001/jama.2021.0202 10.1080/21645515.2022.2071079 10.1038/s41586-021-03777-9 10.1001/jamanetworkopen.2021.6556 10.1093/milmed/usab188 10.1093/ofid/ofab398 10.2147/DDDT.S356951 10.1016/j.ijantimicag.2020.105946 10.1093/cid/ciab305 10.1093/ofid/ofab292 10.1101/2020.09.30.318972 10.1080/14760584.2021.1971522 10.1016/j.jamda.2021.04.023 10.1136/bmj.327.7414.557 10.3201/eid2710.211538 10.1007/s15010-021-01657-y 10.1080/14740338.2023.2130888 10.7759/cureus.16477 10.1016/j.clim.2020.108427 10.1001/jama.2021.8828 10.1093/ofid/ofab331 10.1056/NEJMcp2009249 10.1101/2021.04.30.442182 10.1016/j.cell.2021.03.036 10.1038/s41577-021-00542-x 10.1016/j.ijantimicag.2020.105949 10.2147/DDDT.S293216 10.1093/ofid/ofab254 10.1056/NEJMoa2102685 10.1056/NEJMoa2007764 10.1056/NEJMoa2029849 10.7759/cureus.19747 10.1016/j.jnma.2021.08.036 10.1093/ofid/ofab546 10.1016/j.jmii.2020.07.024 10.1056/NEJMoa2028700 10.7717/peerj.9360 10.1093/ofid/ofab305 10.1093/infdis/jiab377 10.1002/phar.2613 10.1111/irv.12794 10.1055/a-1336-2371 |
| ContentType | Journal Article |
| Copyright | 2023 Tai et al. COPYRIGHT 2023 PeerJ. Ltd. 2023 Tai et al. 2023 Tai et al. |
| Copyright_xml | – notice: 2023 Tai et al. – notice: COPYRIGHT 2023 PeerJ. Ltd. – notice: 2023 Tai et al. 2023 Tai et al. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.7717/peerj.15344 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2167-8359 |
| ExternalDocumentID | oai_doaj_org_article_341a5f11202d4035a0b49a06a157474e PMC10174063 A748441555 37180576 10_7717_peerj_15344 |
| Genre | Meta-Analysis Systematic Review Journal Article |
| GeographicLocations | Iran |
| GeographicLocations_xml | – name: Iran |
| GroupedDBID | 53G 5VS 88I 8FE 8FH AAFWJ AAYXX ABUWG ADBBV ADRAZ AENEX AFKRA AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU CITATION DIK DWQXO ECGQY GNUQQ GROUPED_DOAJ GX1 HCIFZ HYE IAO IEA IHR IHW ITC KQ8 LK8 M2P M48 M7P M~E OK1 PHGZM PHGZT PIMPY PQGLB PQQKQ PROAC PUEGO RPM W2D YAO 3V. CGR CUY CVF ECM EIF H13 NPM PMFND 7X8 5PM |
| ID | FETCH-LOGICAL-c546t-fdfa393b60863f16b6abacb6be44b88465eecaf3e2e48eba0049d10c6929e00e3 |
| IEDL.DBID | M48 |
| ISSN | 2167-8359 |
| IngestDate | Wed Aug 27 01:32:35 EDT 2025 Tue Sep 30 17:13:56 EDT 2025 Thu Sep 04 20:11:51 EDT 2025 Tue Jun 17 21:07:41 EDT 2025 Tue Jun 10 20:51:07 EDT 2025 Thu May 22 21:20:05 EDT 2025 Thu Jan 02 22:51:36 EST 2025 Wed Oct 01 04:46:53 EDT 2025 Thu Apr 24 23:00:32 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | COVID-19 Anti-viral treatment Bamlanivimab Etesevimab Monoclonal antibody |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 2023 Tai et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c546t-fdfa393b60863f16b6abacb6be44b88465eecaf3e2e48eba0049d10c6929e00e3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0003-4415-7811 0000-0003-4630-8724 0000-0003-1677-8901 |
| OpenAccessLink | https://doaj.org/article/341a5f11202d4035a0b49a06a157474e |
| PMID | 37180576 |
| PQID | 2813887005 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_341a5f11202d4035a0b49a06a157474e pubmedcentral_primary_oai_pubmedcentral_nih_gov_10174063 proquest_miscellaneous_2813887005 gale_infotracmisc_A748441555 gale_infotracacademiconefile_A748441555 gale_healthsolutions_A748441555 pubmed_primary_37180576 crossref_citationtrail_10_7717_peerj_15344 crossref_primary_10_7717_peerj_15344 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-05-08 |
| PublicationDateYYYYMMDD | 2023-05-08 |
| PublicationDate_xml | – month: 05 year: 2023 text: 2023-05-08 day: 08 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Diego, USA |
| PublicationTitle | PeerJ (San Francisco, CA) |
| PublicationTitleAlternate | PeerJ |
| PublicationYear | 2023 |
| Publisher | PeerJ. Ltd PeerJ Inc |
| Publisher_xml | – name: PeerJ. Ltd – name: PeerJ Inc |
| References | Lan (10.7717/peerj.15344/ref-40) 2020; 56 Corwin (10.7717/peerj.15344/ref-14) 2021; 8 Lai (10.7717/peerj.15344/ref-39) 2020b; 55 Yang (10.7717/peerj.15344/ref-59) 2021; 15 Planas (10.7717/peerj.15344/ref-48) 2021; 596 Cooper (10.7717/peerj.15344/ref-13) 2021; 8 Gautret (10.7717/peerj.15344/ref-25) 2020; 56 Borrok (10.7717/peerj.15344/ref-4) 2018; 3 Gandhi (10.7717/peerj.15344/ref-22) 2020; 383 Alam (10.7717/peerj.15344/ref-1) 2021; 13 Rainwater-Lovett (10.7717/peerj.15344/ref-49) 2021; 8 Cohen (10.7717/peerj.15344/ref-12) 2021; 326 Zhao (10.7717/peerj.15344/ref-61) 2022; 1 Ganesh (10.7717/peerj.15344/ref-23) 2021a Leavitt (10.7717/peerj.15344/ref-41) 2021; 13 US Food & Drug Administation (10.7717/peerj.15344/ref-55) 2020 Wells (10.7717/peerj.15344/ref-57) 2021 Lai (10.7717/peerj.15344/ref-38) 2020a; 55 Dougan (10.7717/peerj.15344/ref-17) 2022 Rosas (10.7717/peerj.15344/ref-50) 2021; 384 Chiu (10.7717/peerj.15344/ref-9) 2021; 20 Dougan (10.7717/peerj.15344/ref-18) 2021; 385 Higgins (10.7717/peerj.15344/ref-28) 2003; 327 Hsieh (10.7717/peerj.15344/ref-31) 2021; 15 Page (10.7717/peerj.15344/ref-46) 2021; 372 Cohen (10.7717/peerj.15344/ref-11) 2021; 384 Piccicacco (10.7717/peerj.15344/ref-47) 2021; 8 Tuccori (10.7717/peerj.15344/ref-54) 2021; 16 Chiu (10.7717/peerj.15344/ref-10) 2022; 18 Finelli (10.7717/peerj.15344/ref-19) 2021; 4 Chang (10.7717/peerj.15344/ref-5) 2020; 8 Chi (10.7717/peerj.15344/ref-7) 2021; 54 Taylor (10.7717/peerj.15344/ref-53) 2021; 21 Westendorf (10.7717/peerj.15344/ref-58) 2022 Focosi (10.7717/peerj.15344/ref-20) 2022; 23 Hoffmann (10.7717/peerj.15344/ref-30) 2021; 184 Iqbal (10.7717/peerj.15344/ref-32) 2021; 13 Destache (10.7717/peerj.15344/ref-16) 2021; 41 Lundgren (10.7717/peerj.15344/ref-42) 2021; 384 Gottlieb (10.7717/peerj.15344/ref-26) 2021; 325 Rubin (10.7717/peerj.15344/ref-51) 2021; 8 Kumar (10.7717/peerj.15344/ref-37) 2021; 74 Siemieniuk (10.7717/peerj.15344/ref-52) 2020; 370 Chen (10.7717/peerj.15344/ref-6) 2021; 384 Hariyanto (10.7717/peerj.15344/ref-27) 2021; 71 Moreno (10.7717/peerj.15344/ref-44) 2022; 16 Beigel (10.7717/peerj.15344/ref-3) 2020; 383 Yuki (10.7717/peerj.15344/ref-60) 2020; 215 Focosi (10.7717/peerj.15344/ref-21) 2021; 27 Jones (10.7717/peerj.15344/ref-34) 2020 Chilimuri (10.7717/peerj.15344/ref-8) 2022; 113 Johns Hopkins University & Medicine (10.7717/peerj.15344/ref-33) 2021 Murillo (10.7717/peerj.15344/ref-45) 2022; 13 Webb (10.7717/peerj.15344/ref-56) 2021; 8 Dale (10.7717/peerj.15344/ref-15) 2021; 22 Koehler (10.7717/peerj.15344/ref-36) 2021; 1-6 Ganesh (10.7717/peerj.15344/ref-24) 2021b; 224 Karr (10.7717/peerj.15344/ref-35) 2021; 187 Bariola (10.7717/peerj.15344/ref-2) 2021; 8 Mathieu (10.7717/peerj.15344/ref-43) 2020 Hodcroft (10.7717/peerj.15344/ref-29) 2021 |
| References_xml | – volume: 13 start-page: e14933 year: 2021 ident: 10.7717/peerj.15344/ref-1 article-title: Clinical impact of the early use of monoclonal antibody LY-CoV555 (Bamlanivimab) on mortality and hospitalization among elderly nursing home patients: a multicenter retrospective study publication-title: Cureus doi: 10.7759/cureus.14933 – volume: 16 start-page: 1403 issue: 12 year: 2021 ident: 10.7717/peerj.15344/ref-54 article-title: An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future publication-title: Expert Opinion on Drug Discovery doi: 10.1080/17460441.2021.1960819 – volume: 384 start-page: 289 issue: 3 year: 2021 ident: 10.7717/peerj.15344/ref-11 article-title: Monoclonal antibodies to disrupt progression of early COVID-19 infection publication-title: New England Journal of Medicine doi: 10.1056/NEJMe2034495 – year: 2021a ident: 10.7717/peerj.15344/ref-23 article-title: Association of intravenous bamlanivimab use with reduced hospitalization, intensive care unit admission, and mortality in patients with mild to moderate COVID-19 publication-title: medRxiv doi: 10.1101/2021.05.23.21257670 – volume: 3 start-page: 481 issue: 12 year: 2018 ident: 10.7717/peerj.15344/ref-4 article-title: Enhancing IgG distribution to lung mucosal tissue improves protective effect of anti-Pseudomonas aeruginosa antibodies publication-title: JCI Insight doi: 10.1172/jci.insight.97844 – volume: 23 start-page: 29 issue: 1 year: 2022 ident: 10.7717/peerj.15344/ref-20 article-title: Analysis of immune escape variants from antibody-based therapeutics against COVID-19: a systematic review publication-title: International Journal of Molecular Sciences doi: 10.3390/ijms23010029 – volume: 56 start-page: 106103 issue: 3 year: 2020 ident: 10.7717/peerj.15344/ref-40 article-title: Tocilizumab for severe COVID-19: a systematic review and meta-analysis publication-title: International Journal of Antimicrobial Agents doi: 10.1016/j.ijantimicag.2020.106103 – volume: 13 start-page: 1523 issue: 5 year: 2022 ident: 10.7717/peerj.15344/ref-45 article-title: Effect of SARS CoV2-neutralizing monoclonal antibody on hospitalization and mortality in long-term care facility residents publication-title: Aging and Disease doi: 10.14336/AD.2022.0205 – volume: 55 start-page: 105924 issue: 3 year: 2020a ident: 10.7717/peerj.15344/ref-38 article-title: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges publication-title: International Journal of Antimicrobial Agents doi: 10.1016/j.ijantimicag.2020.105924 – volume: 372 start-page: n71 year: 2021 ident: 10.7717/peerj.15344/ref-46 article-title: The PRISMA, 2020 statement: an updated guideline for reporting systematic reviews publication-title: BMJ doi: 10.1136/bmj.n71 – volume: 8 start-page: ofab512 year: 2021 ident: 10.7717/peerj.15344/ref-13 article-title: Real-world assessment of 2879 COVID-19 patients treated with monoclonal antibody therapy: a propensity score-matched cohort study publication-title: Open Forum Infectious Diseases doi: 10.1093/ofid/ofab512 – year: 2022 ident: 10.7717/peerj.15344/ref-17 article-title: Bebtelovimab, alone or together with bamlanivimab and etesevimab publication-title: medRxiv doi: 10.1101/2022.03.10.22272100 – volume: 384 start-page: 905 issue: 10 year: 2021 ident: 10.7717/peerj.15344/ref-42 article-title: A neutralizing monoclonal antibody for hospitalized patients with COVID-19 publication-title: New England Journal of Medicine doi: 10.1056/NEJMoa2033130 – volume: 370 start-page: m2980 year: 2020 ident: 10.7717/peerj.15344/ref-52 article-title: Drug treatments for COVID-19: living systematic review and network meta-analysis publication-title: BMJ doi: 10.1136/bmj.m2980 – volume: 325 start-page: 632 year: 2021 ident: 10.7717/peerj.15344/ref-26 article-title: Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2021.0202 – volume: 18 start-page: 1 year: 2022 ident: 10.7717/peerj.15344/ref-10 article-title: The impact of COVID-19 on routine vaccinations in Taiwan and an unexpected surge of pneumococcal vaccination publication-title: Human Vaccines & Immunotherapeutics doi: 10.1080/21645515.2022.2071079 – volume: 596 start-page: 276 issue: 7871 year: 2021 ident: 10.7717/peerj.15344/ref-48 article-title: Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization publication-title: Nature doi: 10.1038/s41586-021-03777-9 – volume: 4 start-page: e216556 issue: 4 year: 2021 ident: 10.7717/peerj.15344/ref-19 article-title: Mortality among us patients hospitalized with SARS-CoV-2 infection in 2020 publication-title: JAMA Network Open doi: 10.1001/jamanetworkopen.2021.6556 – volume: 187 start-page: e1509 issue: Special Issue_13 year: 2021 ident: 10.7717/peerj.15344/ref-35 article-title: Bamlanivimab use in a military treatment facility publication-title: Military Medicine doi: 10.1093/milmed/usab188 – volume: 8 start-page: ofab398 issue: 8 year: 2021 ident: 10.7717/peerj.15344/ref-49 article-title: Real-world effect of monoclonal antibody treatment in COVID-19 patients in a diverse population in the United States publication-title: Open Forum Infectious Diseases doi: 10.1093/ofid/ofab398 – volume: 16 start-page: 827 year: 2022 ident: 10.7717/peerj.15344/ref-44 article-title: Use of antivirals in SARS-CoV-2 infection. Critical review of the role of remdesivir publication-title: Drug Design, Development and Therapy doi: 10.2147/DDDT.S356951 – volume: 55 start-page: 105946 issue: 4 year: 2020b ident: 10.7717/peerj.15344/ref-39 article-title: Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status publication-title: International Journal of Antimicrobial Agents doi: 10.1016/j.ijantimicag.2020.105946 – volume: 74 start-page: 24 issue: 1 year: 2021 ident: 10.7717/peerj.15344/ref-37 article-title: Real-world experience of bamlanivimab for COVID-19: a case-control study publication-title: Clinical Infectious Diseases doi: 10.1093/cid/ciab305 – volume: 8 start-page: ofab292 issue: 7 year: 2021 ident: 10.7717/peerj.15344/ref-47 article-title: Effectiveness of severe acute respiratory syndrome coronavirus 2 monoclonal antibody infusions in high-risk outpatients publication-title: Open Forum Infectious Diseases doi: 10.1093/ofid/ofab292 – year: 2020 ident: 10.7717/peerj.15344/ref-34 article-title: LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection publication-title: bioRxiv: The Preprint Server for Biology doi: 10.1101/2020.09.30.318972 – volume: 20 start-page: 1 issue: 10 year: 2021 ident: 10.7717/peerj.15344/ref-9 article-title: To mix or not to mix? A rapid systematic review of heterologous prime-boost COVID-19 vaccination publication-title: Expert Review of Vaccines doi: 10.1080/14760584.2021.1971522 – volume: 22 start-page: 1357 year: 2021 ident: 10.7717/peerj.15344/ref-15 article-title: Administration of bamlanivimab to skilled nursing facility residents during a COVID-19 outbreak, January–February 2021, Arizona publication-title: Journal of the American Medical Directors Association doi: 10.1016/j.jamda.2021.04.023 – volume: 327 start-page: 557 issue: 7414 year: 2003 ident: 10.7717/peerj.15344/ref-28 article-title: Measuring inconsistency in meta-analyses publication-title: BMJ doi: 10.1136/bmj.327.7414.557 – year: 2021 ident: 10.7717/peerj.15344/ref-33 article-title: Mortality analyses – volume: 27 start-page: 2728 issue: 10 year: 2021 ident: 10.7717/peerj.15344/ref-21 article-title: Emergence of SARS-COV-2 spike protein escape mutation Q493R after treatment for COVID-19 publication-title: Emerging Infectious Diseases doi: 10.3201/eid2710.211538 – year: 2021 ident: 10.7717/peerj.15344/ref-57 article-title: The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses – volume: 1-6 start-page: 1313 issue: 6 year: 2021 ident: 10.7717/peerj.15344/ref-36 article-title: Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany publication-title: Infection doi: 10.1007/s15010-021-01657-y – volume: 1 start-page: 1 issue: 1 year: 2022 ident: 10.7717/peerj.15344/ref-61 article-title: Evaluation of adverse events of bamlanivimab, bamlanivimab/etesevimab used for COVID-19 based on FAERS database publication-title: Expert Opinion on Drug Safety doi: 10.1080/14740338.2023.2130888 – volume: 13 start-page: e16477 year: 2021 ident: 10.7717/peerj.15344/ref-32 article-title: Efficacy of bamlanivimab in reducing hospitalization and mortality rates in COVID-19 patients in a rural community publication-title: Cureus doi: 10.7759/cureus.16477 – volume: 215 start-page: 108427 year: 2020 ident: 10.7717/peerj.15344/ref-60 article-title: COVID-19 pathophysiology: a review publication-title: Clinical Immunology (Orlando, Florida) doi: 10.1016/j.clim.2020.108427 – volume: 326 start-page: 46 year: 2021 ident: 10.7717/peerj.15344/ref-12 article-title: Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2021.8828 – volume: 8 start-page: ofab331 issue: 7 year: 2021 ident: 10.7717/peerj.15344/ref-56 article-title: Real-world effectiveness and tolerability of monoclonal antibody therapy for ambulatory patients with early COVID-19 publication-title: Open Forum Infectious Diseases doi: 10.1093/ofid/ofab331 – year: 2020 ident: 10.7717/peerj.15344/ref-43 – volume: 383 start-page: 1757 issue: 18 year: 2020 ident: 10.7717/peerj.15344/ref-22 article-title: Mild or moderate COVID-19 publication-title: New England Journal of Medicine doi: 10.1056/NEJMcp2009249 – year: 2020 ident: 10.7717/peerj.15344/ref-55 article-title: Emergency use authorization—archived information – year: 2022 ident: 10.7717/peerj.15344/ref-58 article-title: LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants publication-title: bioRxiv: The Preprint Server for Biology doi: 10.1101/2021.04.30.442182 – volume: 184 start-page: 2384–2393.e2312 issue: 9 year: 2021 ident: 10.7717/peerj.15344/ref-30 article-title: SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies publication-title: Cell doi: 10.1016/j.cell.2021.03.036 – volume: 21 start-page: 382 issue: 6 year: 2021 ident: 10.7717/peerj.15344/ref-53 article-title: Neutralizing monoclonal antibodies for treatment of COVID-19 publication-title: Nature Reviews Immunology doi: 10.1038/s41577-021-00542-x – volume: 56 start-page: 105949 issue: 1 year: 2020 ident: 10.7717/peerj.15344/ref-25 article-title: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial publication-title: International Journal of Antimicrobial Agents doi: 10.1016/j.ijantimicag.2020.105949 – volume: 15 start-page: 1213 year: 2021 ident: 10.7717/peerj.15344/ref-59 article-title: Potential anti-coronavirus agents and the pharmacologic mechanisms publication-title: Drug Design, Development and Therapy doi: 10.2147/DDDT.S293216 – volume: 8 start-page: ofab254 year: 2021 ident: 10.7717/peerj.15344/ref-2 article-title: Impact of bamlanivimab monoclonal antibody treatment on hospitalization and mortality among nonhospitalized adults with severe acute respiratory syndrome coronavirus 2 infection publication-title: Open Forum Infectious Diseases doi: 10.1093/ofid/ofab254 – volume: 385 start-page: 1382 issue: 15 year: 2021 ident: 10.7717/peerj.15344/ref-18 article-title: Bamlanivimab plus etesevimab in mild or moderate COVID-19 publication-title: The New England Journal of Medicine doi: 10.1056/NEJMoa2102685 – volume: 383 start-page: 1813 issue: 19 year: 2020 ident: 10.7717/peerj.15344/ref-3 article-title: Remdesivir for the treatment of COVID-19 final report publication-title: New England Journal of Medicine doi: 10.1056/NEJMoa2007764 – volume: 384 start-page: 229 issue: 3 year: 2021 ident: 10.7717/peerj.15344/ref-6 article-title: SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19 publication-title: New England Journal of Medicine doi: 10.1056/NEJMoa2029849 – volume: 13 start-page: e19747 year: 2021 ident: 10.7717/peerj.15344/ref-41 article-title: Real world utilization of bamlanivimab at a rural community hospital publication-title: Cureus doi: 10.7759/cureus.19747 – volume: 113 start-page: 701 issue: 6 year: 2022 ident: 10.7717/peerj.15344/ref-8 article-title: Implementation and outcomes of monoclonal antibody infusion for COVID-19 in an inner-city safety net hospital: a South-Bronx experience publication-title: Journal of the National Medical Association doi: 10.1016/j.jnma.2021.08.036 – volume: 8 start-page: ofab546 issue: 12 year: 2021 ident: 10.7717/peerj.15344/ref-51 article-title: Bamlanivimab efficacy in older and high-BMI outpatients with COVID-19 selected for treatment in a lottery-based allocation process publication-title: Open Forum Infectious Diseases doi: 10.1093/ofid/ofab546 – volume: 54 start-page: 69 issue: 1 year: 2021 ident: 10.7717/peerj.15344/ref-7 article-title: Clinical features of neonates born to mothers with coronavirus disease-2019: a systematic review of 105 neonates publication-title: Journal of Microbiology, Immunology and Infection doi: 10.1016/j.jmii.2020.07.024 – volume: 384 start-page: 1503 issue: 16 year: 2021 ident: 10.7717/peerj.15344/ref-50 article-title: Tocilizumab in hospitalized patients with severe COVID-19 pneumonia publication-title: New England Journal of Medicine doi: 10.1056/NEJMoa2028700 – volume: 8 start-page: e9360 issue: 14 year: 2020 ident: 10.7717/peerj.15344/ref-5 article-title: COVID-19: Taiwan’s epidemiological characteristics and public and hospital responses publication-title: PeerJ doi: 10.7717/peerj.9360 – year: 2021 ident: 10.7717/peerj.15344/ref-29 article-title: CoVariants – volume: 8 start-page: ofab305 issue: 7 year: 2021 ident: 10.7717/peerj.15344/ref-14 article-title: The efficacy of bamlanivimab in reducing emergency department visits and hospitalizations in a real-world setting publication-title: Open Forum Infectious Diseases doi: 10.1093/ofid/ofab305 – volume: 224 start-page: 1278 issue: 8 year: 2021b ident: 10.7717/peerj.15344/ref-24 article-title: Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019 publication-title: The Journal of Infectious Diseases doi: 10.1093/infdis/jiab377 – volume: 41 start-page: 743 issue: 9 year: 2021 ident: 10.7717/peerj.15344/ref-16 article-title: Bamlanivimab use in mild-to-moderate COVID-19 disease: a matched cohort design publication-title: Pharmacotherapy doi: 10.1002/phar.2613 – volume: 15 start-page: 121 issue: 1 year: 2021 ident: 10.7717/peerj.15344/ref-31 article-title: Intravenous peramivir vs oral oseltamivir in high-risk emergency department patients with influenza: results from a pilot randomized controlled study publication-title: Influenza and Other Respiratory Viruses doi: 10.1111/irv.12794 – volume: 71 start-page: 265 issue: 05 year: 2021 ident: 10.7717/peerj.15344/ref-27 article-title: Efficacy and safety of tocilizumab for coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis publication-title: Drug Research (Stuttgart) doi: 10.1055/a-1336-2371 |
| SSID | ssj0000826083 |
| Score | 2.2917948 |
| SecondaryResourceType | review_article |
| Snippet | Coronavirus disease 2019 (COVID-19) has caused an enormous loss of life worldwide. The spike protein of the severe acute respiratory syndrome coronavirus 2 is... Background Coronavirus disease 2019 (COVID-19) has caused an enormous loss of life worldwide. The spike protein of the severe acute respiratory syndrome... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e15344 |
| SubjectTerms | Analysis Anti-viral treatment Antibodies, Monoclonal - adverse effects Bamlanivimab Coronaviruses COVID-19 Drugs and Devices Etesevimab Hospitalization Humans Infectious Diseases Iran Monoclonal antibody Mortality Outpatients Patient outcomes Pharmacology Respiratory Medicine SARS-CoV-2 Severe acute respiratory syndrome |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQD4gL4ptAASNVQkKKmsR2NuFWClVBKlwo6s0aO7a60m5S7Wb5W_2LnbHdZSOQuHDZQzwbxZ7JzBtn5pmxAyNsU0kv8toplUvTiNx4YsLEZMKaGf4G7s6zb_Xpufx6oS52jvqimrBIDxwX7hC9LCiPqKCoOlkIBYWRLRQ1lAqRsHTkfTGM7SRTwQcjakZwERvyZpiyHF45t0K_oISUkxAUmPr_9Mc7AWlaLLkTfU4esPsJNvKj-LgP2R3XP2J3z9KH8cfsOrIQr_nguYHlAvr5r_kSDIfF0Ds-rPi852hcmAcHVXDaf-W06eqiHF5aow8JhdUjv0yniaQmTQ59x5cBqCNop1sNmzExsq7jrY6___zyKS_bDxz4b3ZoHjtj4v_dCDkkDpQn7Pzk84_j0zydxZBbJesx950H0QqDq1oLX9amBgPW1MZJVDCCGOWcBS9c5WTjDFDm0ZWFrRF-uaJw4inb63HCzxk3zQz1CWVnWydnnaGdWPCln1WmaysjM_b-Vj3aJqJyOi9joTFhIV3qoEsddJmxg63wVeTn-LvYR9LzVoRItcMFNDWdTE3_y9Qy9oasRMcO1a1r0EfEx0rATGXsXZAg54CPbCH1OODEiWZrIrk_kcSX2k6G395aoqYhqoTr3bBZ66opBQYGdJ4ZexYtczsrgUAD8XedsWZis5NpT0f6-WXgFCfPjNhOvPgfC_WS3cOhWBfa7LO9cbVxrxC7jeZ1eE1vAHuKRXU priority: 102 providerName: Directory of Open Access Journals |
| Title | Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37180576 https://www.proquest.com/docview/2813887005 https://pubmed.ncbi.nlm.nih.gov/PMC10174063 https://doaj.org/article/341a5f11202d4035a0b49a06a157474e |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2167-8359 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000826083 issn: 2167-8359 databaseCode: KQ8 dateStart: 20130101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2167-8359 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000826083 issn: 2167-8359 databaseCode: DOA dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2167-8359 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000826083 issn: 2167-8359 databaseCode: DIK dateStart: 20130101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 2167-8359 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000826083 issn: 2167-8359 databaseCode: GX1 dateStart: 20130101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2167-8359 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000826083 issn: 2167-8359 databaseCode: M~E dateStart: 20130101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2167-8359 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000826083 issn: 2167-8359 databaseCode: RPM dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2167-8359 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000826083 issn: 2167-8359 databaseCode: BENPR dateStart: 20130212 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2167-8359 dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0000826083 issn: 2167-8359 databaseCode: M48 dateStart: 20131101 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwELVKKyEuiG8CZTFSJSSklCR2nIQLaktLQdqCEIv2FtmOQ1faTcomi-BX8ReZsb1LAz1wySGeRBnPeOaNYz8TsqeYzhNes1CYNA25ylmoamTChGJCqwyulrtzfCZOJ_z9NJ1ukfVhnL4DuytLOzxParKc7__49vM1DHjAr_sZVCMvL4xZwpBPGefXyA6kpATde-xxvg3JAKIjS8mZIM83oI7C7dX7-_lBdrIk_v-G6ku5ariO8lJiOrlFbnpESQ-cC9wmW6a5Q66P_T_zu-SXIyjuaFtTJRdz2cy-zxZSUTlvG0PbJZ01FPwOSmRrJYpTsxTnY42Tg1sdhBe75rqn5_6gEb9_k8qmogvbfYDn8VXtqvdkrZ171dGHL-_ehHHxikr6hziauk0z7nnTy1B6epR7ZHJy_PnoNPTHNIQ65aIP66qWrGAKeliwOhZKSCW1EspwsD3gm9QYLWtmEsNzoyQWJVUcaQHIzESRYffJdgMKPyRU5VkdxzKudGF4VimcpJV1XGeJqopE8YC8WJun1J7DHI_SmJdQy6AtS2vL0toyIHsb4QtH3XG12CHaeSOCfNv2Rrv8WvrhW0Kulyl8WhIlFY9YKiPFCxkJGadQj3ETkKfoJaXbvLqJGuUBUrUiZksD8txKoCfDJ2vptz-A4sjANZDcHUjCeNeD5mdrTyyxCRfJNaZddWWSxwxyBsTVgDxwnrnRigEGAWguApIPfHag9rClmZ1bunEM2gD72KP_1uAxuQEd5daF5rtku1-uzBPAbr0akZ3D47OPn0Z27gOub6fxyI7V3xQmSs4 |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+bamlanivimab+alone+or+in+combination+with+etesevimab+on+subsequent+hospitalization+and+mortality+in+outpatients+with+COVID-19%3A+a+systematic+review+and+meta-analysis&rft.jtitle=PeerJ+%28San+Francisco%2C+CA%29&rft.au=Tai%2C+Yu-Lin&rft.au=Lee%2C+Ming-Dar&rft.au=Chi%2C+Hsin&rft.au=Chiu%2C+Nan-Chang&rft.date=2023-05-08&rft.pub=PeerJ.+Ltd&rft.issn=2167-8359&rft.eissn=2167-8359&rft.volume=11&rft.spage=e15344&rft_id=info:doi/10.7717%2Fpeerj.15344&rft.externalDocID=A748441555 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2167-8359&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2167-8359&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2167-8359&client=summon |